Johnson & Johnson (JNJ) Rating Reiterated by HC Wainwright

Johnson & Johnson (NYSE:JNJ)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Wednesday.

JNJ has been the subject of several other research reports. Credit Suisse Group set a $149.00 price target on Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, October 14th. Jefferies Financial Group set a $145.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Sanford C. Bernstein assumed coverage on Johnson & Johnson in a research report on Wednesday, June 27th. They set a “market perform” rating and a $129.00 price target on the stock. Finally, Goldman Sachs Group upgraded Johnson & Johnson from a “sell” rating to a “neutral” rating in a research report on Thursday, July 12th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the stock. Johnson & Johnson presently has an average rating of “Hold” and a consensus target price of $141.54.

JNJ opened at $138.41 on Wednesday. The stock has a market cap of $374.16 billion, a PE ratio of 18.95, a P/E/G ratio of 2.21 and a beta of 0.70. Johnson & Johnson has a 52-week low of $118.62 and a 52-week high of $148.32. The company has a quick ratio of 1.33, a current ratio of 1.65 and a debt-to-equity ratio of 0.47.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion during the quarter, compared to the consensus estimate of $20.05 billion. Johnson & Johnson had a return on equity of 34.97% and a net margin of 1.89%. The firm’s revenue was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.90 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 8.16 earnings per share for the current year.

In related news, CAO Ronald A. Kapusta sold 7,899 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Michael E. Sneed sold 29,000 shares of the firm’s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the transaction, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.

Several institutional investors have recently bought and sold shares of JNJ. Phocas Financial Corp. raised its position in shares of Johnson & Johnson by 999,927.7% during the 2nd quarter. Phocas Financial Corp. now owns 129,463,583 shares of the company’s stock valued at $1,571,000 after buying an additional 129,450,637 shares in the last quarter. Glenmede Trust Co. NA boosted its stake in shares of Johnson & Johnson by 149.8% during the 2nd quarter. Glenmede Trust Co. NA now owns 22,174,682 shares of the company’s stock valued at $2,690,676,000 after purchasing an additional 13,295,992 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Johnson & Johnson by 4.7% during the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock valued at $22,476,102,000 after purchasing an additional 7,853,141 shares in the last quarter. Boston Partners boosted its stake in shares of Johnson & Johnson by 68.7% during the 1st quarter. Boston Partners now owns 12,783,909 shares of the company’s stock valued at $1,638,258,000 after purchasing an additional 5,207,124 shares in the last quarter. Finally, Fundsmith Equity Fund L.P. purchased a new position in Johnson & Johnson during the 2nd quarter valued at about $552,762,000. Hedge funds and other institutional investors own 66.67% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: What are the Benefits of Index Funds?

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply